NanoVibronix Inc.

03/08/2019 | Press release | Distributed by Public on 03/08/2019 08:04

NanoVibronix CEO to Present UroShield(R) at the U.S. National Institutes of Health's Catheter-Associated Urinary Tract Infections Technology Workshop

ELMSFORD, NY / ACCESSWIRE / March 8, 2019 / NanoVibronix, Inc. (NASDAQ: NAOV), a medical device company utilizing its proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced that CEO Brian Murphy will present UroShield® at the Catheter-Associated Urinary Tract Infections Technology Workshop hosted by National Institutes of Health (NIH) and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) on Monday, March 11, 2019 at the NIH's Natcher Conference Center in Bethesda, Maryland.

UroShield is an ultrasound-based product that is designed to prevent bacterial colonization and biofilm on indwelling urinary catheters and increase antibiotic efficacy, ultimately reducing the incidence of catheter-associated urinary tract infections (CAUTI). UroShield is also intended to decrease pain, discomfort, and blockage associated with urinary catheter use.

In a recent published study, UroShield reduced Colony Forming Units (CFU) count from over 100,000 to 10,000 CFU or less in 25 out of 29 patients in the treatment group. Additionally, there were no reported infections in the treatment group versus 27% symptomatic treated infections in the control group during the treatment period.

The Company also announced it plans to present new summary data from a recently completed in vitro study performed at the University of Southampton on UroShield's impact on E. coli, Proteus and Pseudomonas.

The purpose of the conference is to promote the development of new or improved technologies to reduce the incidence and severity of catheter-associated urinary tract infections. Catheter-associated urinary tract infections (CAUTIs) are the most common healthcare associated infections. Between 15-25% of hospitalized patients receive urinary catheters during their hospital stay, and prolonged use of a urinary catheter is a risk factor for developing a CAUTI. CAUTIs are responsible for increased morbidity and mortality (e.g., due to bloodstream infections), excess length of stay, increased cost, and unnecessary antimicrobial use.

For more information about the conference please visit: https://www.niddk.nih.gov/news/meetings-workshops/2019/catheter-associated-urinary-tract-infections-technology-workshop.

About NanoVibronix

NanoVibronix, Inc. (NASDAQ: NAOV) is a medical device company headquartered in Elmsford, New York with research and development in Nesher, Israel, that is focused on developing medical devices utilizing its proprietary and patented low intensity surface acoustic wave (SAW) technology. The company's technology allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications, including the disruption of biofilms and bacteria colonization, as well as providing pain relief. The devices can be administered at home, without the assistance of medical professionals. The company's primary products include PainShield®, UroShield® and WoundShield®. Additional information about the company is available at: www.nanovibronix.com.

Forward-looking Statements

This press release contains ''forward-looking statements.'' Such statements may be preceded by the words ''intends,'' ''may,'' ''will,'' ''plans,'' ''expects,'' ''anticipates,'' ''projects,'' ''predicts,'' ''estimates,'' ''aims,'' ''believes,'' ''hopes,'' ''potential'' or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Investor Contact

David Waldman
Crescendo Communications
[email protected]
212-671-1021

SOURCE: NanoVibronix, Inc.

Released March 8, 2019